Daniel Bedinger helped launch Carterra’s LSA platform and now leads the company’s global Application Science team. He has over two decades of experience in the generation and characterization of therapeutic monoclonal antibodies—most notably at Xoma and Abgenix. Dan is a co-author on the recent Science paper by Hastie et al at the La Jolla Institute of Immunology on defining variant resistant epitopes targeted by SARS-CoV 2antibodies.  Daniel earned his Ph.D. from UC Davis in Cellular and Molecular Physiology.

Several recent examples in picking therapeutic candidates rapidly have been published highlighting the utility of high-resolution competition-based epitope analysis in the characterization of diverse monoclonal antibody panels.   Detailed competition-based epitope binning can be used to cluster related antibodies into binding classes which inform variant resistance, avidity, and activity.  Furthermore, this information can enable a more detailed understanding of mAb sequence sets which are generated from diverse panels of putative binders from next generation sequencing based discovery approaches.  The Carterra LSA instrument and Epitope software enable this analysis at an unrivaled scale and level of detail.